Anteris Technologies (ASX:AVR) completed its initial public offering in the US, issuing 14.8 million shares at $6 each to raise gross proceeds of $88.8 million, according to a Tuesday filing with the Australian bourse.
The company's stock started trading on the Nasdaq Global Market under the ticker "AVR" on Dec. 13, the filing said.
The company will also list its Chess Depositary Interests on the Australian stock exchange under the ticker "AVR," the filing added.
The company plans to use the proceeds from the IPO to fund the development of its DurAVR transcatheter heart valve and a global clinical study for the valve to treat aortic stenosis, with remaining funds for working capital and debt repayment.
Shares of the company fell nearly 15% in recent Tuesday trade.
Price (AUD): $9.00, Change: $-1.54, Percent Change: -14.61%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。